Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2018-08-30 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于第二期限制性股票激励计划首次授予部分第二次解锁上市流通的提示性公告
Director's Dealing Classification · 95% confidence The document is a detailed announcement regarding the unlocking and listing of restricted shares under the company's second restricted stock incentive plan. It includes specifics about the number of shares unlocked, the conditions met for unlocking, the dates of unlocking, and the impact on share capital structure. The document is not a full annual or interim financial report, nor is it a simple announcement of a report publication. It is not a call transcript, audit report, or legal proceeding update. It primarily concerns management decisions and disclosures about stock incentive plans and share unlockings, which relate to changes in senior management shareholdings and stock incentive arrangements. This fits best under the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives, including stock incentive plan unlockings and related share transactions. The document length (6167 characters) and detailed content support this classification with high confidence.
2018-08-30 Chinese
关于回购注销部分限制性股票的减资公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement by Anhui Anke Biotechnology (Group) Co., Ltd. regarding the repurchase and cancellation of part of its restricted shares, which leads to a reduction in registered capital. It details the board meeting decision, the number of shares repurchased and cancelled, the impact on registered capital, and legal notifications to creditors. The content focuses on a capital change event related to share repurchase and cancellation, not a financial report or earnings release. The document length is short (1001 characters) and is a formal announcement of a capital change event. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2018-08-23 Chinese
关于第六届监事会第十三次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 13th meeting of the 6th Supervisory Board of Anhui Anke Biological Engineering (Group) Co., Ltd. It includes approvals related to the 2018 semi-annual report, stock incentive plans, stock repurchases, and amendments to the company's articles of association. The document does not contain the full semi-annual report or detailed financial statements but rather the supervisory board's approval and verification of the report and related corporate governance matters. It is a formal announcement of board/management decisions and approvals, not the report itself or a detailed financial report. Therefore, it fits best under Board/Management Information (MANG). The document length is 2454 characters, which is relatively short and consistent with an announcement rather than a full report.
2018-08-23 Chinese
2018年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "安徽安科生物工程(集团)股份有限公司 2018 年半年度报告全文" which translates to Anhui Anke Biotechnology (Group) Co., Ltd 2018 Semi-Annual Report Full Text. It contains detailed financial data, business overview, management discussion and analysis, risk factors, and operational details for the first half of 2018 (reporting period from January 1, 2018 to June 30, 2018). The document includes comprehensive financial indicators, business segments, R&D progress, and other substantive financial and operational information typical of an Interim / Quarterly Report. The length is about 15,000 characters, indicating a full report rather than a brief announcement or summary. There is no indication that this is an announcement of a report publication or a certification letter. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2018
2018-08-23 Chinese
安徽天禾律师事务所关于公司第二期限制性股票激励计划首次授予的限制性股票第二次解锁、第二期限制性股票激励计划预留授予的限制性股票第一次解锁及回购注销部分限制性股票相关事项之法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the company's second phase restricted stock incentive plan, including the unlocking of restricted stocks and the repurchase and cancellation of some restricted stocks. It references specific legal and regulatory frameworks such as the Securities Law, the Stock Incentive Management Measures, and the company's internal stock incentive plan. The document details approvals by the board, supervisory board, and shareholders, conditions for unlocking stocks, and repurchase prices. It is a standalone legal opinion related to stock incentive plan implementation and compliance, not a full annual or interim financial report, earnings release, or management discussion. It does not contain financial statements or earnings data but focuses on legal compliance and authorization of stock incentive plan actions. Therefore, it fits best under Audit Report / Information (AR) as it is a legal opinion on compliance and authorization related to stock incentive plans, which is a type of audit/legal compliance report rather than a financial report or announcement. FY 2018
2018-08-23 Chinese
公司章程修正案
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement of amendments to the company's articles of association (公司章程修正案), specifically regarding the reduction of registered capital and corresponding changes in share capital numbers. It references approval by the board and compliance with regulatory guidelines from the China Securities Regulatory Commission. The content is focused on governance and capital structure changes but does not contain financial statements or detailed financial performance data. The document length is short (528 characters), and it is a direct announcement of changes to the company's charter rather than a full report or financial filing. Therefore, it fits best under Share Issue/Capital Change (SHA) as it involves changes in registered capital and share capital structure.
2018-08-23 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.